Lv6195
1708 积分 2025-11-28 加入
Radioactive ADME Demonstrates ARV-110’s High Druggability Despite Low Oral Bioavailability
13天前
已完结
Preclinical translational physiologically based pharmacokinetic modeling for predicting human pharmacokinetics of proteolysis targeting chimeras: Case studies of vepdegestrant (ARV-471) and bavdegalutamide (ARV-110)
13天前
已完结
PBPK Modelling of PROTACs: Learnings from ARV-110 as a Case Example
13天前
已完结
Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development
15天前
已完结
Enabling Access to sp3‐Enriched Targeted Protein Degraders via Redox‐Neutral Radical Cross‐Coupling
1个月前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
2个月前
已完结
Systematic risk identification and assessment using a new risk map in pharmaceutical R&D
3个月前
已完结
Development of Scalable Synthesis of RAS Inhibitor’s Indole Building Block via Flow Chemistry
4个月前
已完结
皖公网安备34019202002308
